Hans Keirstead

Hans Keirstead is a prominent figure in the biotechnology and healthcare sectors, currently serving as the Chief Executive Officer of the Human Immunome Project since May 2023, where the focus is on generating extensive immunological datasets and developing AI models to enhance medical research. In addition, Hans holds the position of Chairman of the Board at Immunis, Inc., which specializes in treatments for immune deficits, and AIVITA Biomedical, Inc., which is advancing regenerative medicine initiatives. Active in governance and charity, Hans also serves as Chairman of the Board of Directors for the National Institute of Child Sexual Assault and Mission Plasticos, among other board memberships, contributing to various initiatives aimed at improving health and supporting vulnerable populations. Educational achievements include a Post Doctoral degree in Neurobiology from the University of Cambridge and a Ph.D. in Neurobiology from The University of British Columbia.